维普期刊资源整合服务平台（V6.5）

69篇 您的检索式：作者名="Negrier S"

选中清除导出查看参考文献查看引证文献引用追踪共4页首页上一页第1页下一页末页 /4 跳转

	题名	作者	年代	出处	被引量
1	Safety and efficacy of subcutaneous and continuous intravenous itffusion rlL-2 in patients with metastatic renal cell carcinoma 显示文摘	Geertsen PF Gore ME Negrier S	2004	Br J Cancer2004，90，6：	1
2	Sequential sorafenib and sunitinib for renal cell carcinoma显示文摘	Sablin M P Negrier S Ravaud A	2009	J Urol2009，182，1：	1
3	Medroxyprogeste- rone,interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results from a randomized controlled trial 显示文摘	Negrier S Perol D Ravaud C	2007	Cancer2007，110，11：	1
4	Phase ID trial of bev-acizumab plus interferon alfa-2a in patients with metastatic renalcell carcinoma ( AVOREN ) : Final analysis of overall survival显示文摘	Escudier B Bellmunt J Negrier S	2010	J Clin Oncol2010，28，13：	1
5	Phase Ⅲ trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN):final analysis of overall survival显示文摘	ESCUDIER B BELLMUNT J NEGRIER S	2010	J Clin Oncol2010，28，13：	1
6	Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival 显示文摘	Escudier B Bellmunt J Negrier S	2010	J Clin Oncol2010，28，13：	1
7	Can the combination of temsirolimus and bevacizumab improve the treatment of metastatic renal cell carcinoma (mR- CC)? Results of the randomized TORAVA phase II trial 显示文摘	Escudier B J Negrier S Gravis G	2010	J Clin Oncol (Meeting Abstracts)2010，28，15：	1
8	Recombinant hu- man interleukin-2 recombinant human interferonalfa-2a or both in metastatic renal cell careinoma显示文摘	NEGRIER S ESCUDIER B LASSET C	2008	Engl J Med2008，338，：	1
9	PhaseⅢtrial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma(AVOREN):final analysis of overall survival显示文摘	Escudier B Bellmunt J Negrier S	2010	J Clin Oncol2010，28，13：	1
10	Nonmetastatic renal cell carcinoma: is it really possible to define rational guidelines for post treatment follow up显示文摘	Rouviere O Bouvier R Negrier S	2006	Nat Clin Pract Oncol2006，3，：	1
11	A phase Ⅱ study of docetaxel-irinotecan combination in advanced pancreatic cancer显示文摘	Kurtz JE Negrier S Husseini F	2003	Hepatogastroenterology2003，50，50：	1
12	Nonmetastatic re- nal-cell carcinoma; is it really possible to define rational guidelines for post-treatment follow-up? 显示文摘	Rouviere O Bouvier R Negrier S	2006	Nat Clin Pract Oncol2006，3，4：	1
13	Phase llI trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma(AVOREN) :final analysis of overall survival 显示文摘	ESCUDIER B BELLMUNT J NEGRIER S	2010	Clin Onco12010，28，13：	1
14	Safety and efficacy of subcutaneous and continuous intravenous infusion rIL-2 in patients with metastatic renal cell carcinoma显示文摘	Geertsen PF Gore ME Negrier S	2004	Br J Cancer2004，90，6：	1
15	Long-term follow- up of patients with metastatic renal cell carcinoma treated with intravenous recombinant interleukin-2 in Europe 显示文摘	Negrier S Maral J Drevon M	2000	Cancer J Sci Am2000，6，：	1
16	Recombinant human interleukin -2,Recombinant human interferon -alfa -2a,or both in metastatic renal cell carcinoma显示文摘	Negrier S Escudier B Lasset C	1998	N Engl J Med1998，338，：	1
17	long-term follow-up of patients with metastic renal cell careinoma treated with intravenous recombinant IL-2 in Europe显示文摘	Negrier S	2000	Caneer J Sci Am2000，2，61：	1
18	Randomized study of intravenous versus subcutaneous interleukin-2, and IFN alpha in patients with good prognosis metastatic renal cancer 显示文摘	Negrier S Perol D Ravand A	2008	Clin Cancer Res2008，14，18：	1
19	Sequential sorafenib and sunitinib for renal cell carcinoma 显示文摘	Sablin MP Negrier S Ravaud A	2009	J Urol2009，182，1：	1
20	显示文摘	Negrier S Escudier B Lassett C	1998	N Engl J Med1998，338，：	1

返回顶部每页显示：

共4页首页上一页第1页下一页末页 /4 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示